Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Limited-Stage SCLC: Is Immunotherapy an Option?

April 13th 2020

Small-Cell Lung Cancer: The IMpower133 and CASPIAN trials

April 13th 2020

Stage III NSCLC Progression Treatment Strategy

April 13th 2020

Stage III NSCLC: When to Start Durvalumab

April 13th 2020

Unresectable Stage III Lung Cancer Management

April 13th 2020

Brain Metastatic NSCLC: Targeted Therapy Approach

April 13th 2020

ALK-Rearranged & MET Exon 14 NSCLC Treatment Options

April 13th 2020

When to Re-Treat with Osimertinib

April 13th 2020

Oligometastatic and Small Cell Transformation Management

April 13th 2020

Upfront Targeted Treatment Approach

April 13th 2020

Lung Cancer Molecular Testing Protocol

April 13th 2020

When to Use the CheckMate-227 Regimen

April 13th 2020

The IMpower150 Regimen

April 13th 2020

How Long to Continue Immunotherapy

April 13th 2020

Immunotherapy and Brain Metastatic Lung Cancer

April 13th 2020

PD-L1 Less Than 49%: Available Treatments

April 13th 2020

Progression on Immunotherapy: Treatment Approach

April 13th 2020

Therapy Approach for PD-L1 Over 50% Lung Cancer

April 13th 2020

Work-Up and Management of Nondriver Metastatic Lung Cancer

April 13th 2020

New Frontier for Genomics: Radiotherapy in Early Breast Cancer

April 8th 2020

By individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.